A small clinical correspondence reports that patients with relapsed or refractory multiple myeloma on extended-interval teclistamab plus talquetamab avoided repeat step-up dosing across 8- to 12-week gaps after achieving at least complete response. The six-patient series reported no acute inflammatory toxicities despite skipping the conventional step-up re-initiation. Teclistamab and talquetamab are CD3 T-cell engagers where early-phase cytokine release syndrome and immune effector cell-associated neurotoxicity require structured step-up dosing and monitoring. Standard prescribing information recommends repeating step-up after prolonged delays, so the report challenges an assumption in real-world dosing continuity. For clinicians and treatment administrators, the potential benefit is reduced patient burden and operational strain during late phases where toxicities and infections remain common. However, the correspondence is limited by sample size and the need for broader confirmation. The immediate relevance is practical: it offers a data point for teams considering individualized scheduling strategies for patients with deep responses when repeated step-up procedures could be burdensome.